ArticlePathogens and disease2025
Eugenol nanoparticle as a therapeutic agent against Pseudomonas infection in mice.
Article in Pathogens and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
We reported earlier about development of nano-formulation of an essential oil "eugenol" through its entrapment within animal protein "gelatin," using a simple ultrasonication technique, followed by purification via ultracentrifugation. The synthesized eugenol nanoparticle (ENP) exhibited promising antibacterial and antibiofilm activity on pathogenic strain Pseudomonas aeruginosa MTCC 2488 in vitro. Here, we report on in vivo therapeutic efficacy of ENP against Pseudomonas-administered lung infection, developed in BALB/c mice. Our findings revealed that ENP treatment significantly reduced bacterial burden in infected lung tissues and promoted recovery from infection-associated weight loss, hypothermia, and fluid accumulation in mice. In addition, histopathological and immunological studies showed that the elevated level of inflammatory cytokines TNF-α, IL-1β, MCP-1, GM-CSF, and IFN-γ in lung tissue, serum, and broncho-alveolar lavage (BAL) fluid of Pseudomonas-infected mice were considerably attenuated to almost normal level by ENP treatment. Notably, free eugenol had not so high antipseudomonal action as ENP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.